课题基金 / 基金详情

Business and regulatory development for Integrating sleep enhancement technology into clinical practice

Business and regulatory development for Integrating sleep enhancement technology into clinical practice
将睡眠增强技术融入临床实践的业务和监管发展
批准号:
10428404
负责人:
Daniel Gartenberg
金额:
$5.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-05-01 至 2023-05-31

项目摘要

项目成果

Daniel Gartenberg的其他基金

相关文献

中文摘要
翻译
SleepSpace使用SaaS平台和设备来监控用户的睡眠质量并提供
英文摘要
SleepSpace uses a SaaS platform and device to monitor the quality of a user’s sleep and provide feedback aimed at improving a user’s “Sleep Journey.” The system connects patients who suffer from insomnia and sleep apnea to doctors and psychologists. SleepSpace provides tools to the provider to improve their diagnoses and treatment of these disorders. We request assistance with assessing the payer reimbursement landscape and developing a business model around potential reimbursement opportunities, including actigraphy and remote patient monitoring codes (i.e. CPT codes 99453, 99454, 99457, and 99484). The use of these codes will be investigated both for our novel hardware system for measuring sleep, and via our software that integrates with Apple product like the iPhone, Apple Watch, and HomePod. If insurance will not reimburse for the use of these codes, we will explore business models around selling the product to clinicians for improving the efficacy of their practice and increasing their revenue through increased charges to the patient, outside of the healthcare payment system. During Phase I of the project we will complete a pre-submission to the FDA and have written feedback from them regarding the appropriate regulatory pathway for our SaaS platform/device/accessory, including possible 510(k) approval. This phase will involve an information gathering session, drafting the submission, and a follow-up questions meeting to process the FDA’s feedback. This will be followed by attending the meeting with the FDA to review and approve their meeting minutes. We will understand the most up-to-date RPM and virtual care reimbursement requirements and the resulting business model implications. We will receive marketing materials and provided with a comprehensive RPM/virtual care FAQs document with answers to customers’ frequently asked questions, allowing SleepSpace to educate its team and close deals faster. In order to complete this task we will collaborate with Nixon Gwilt Law, a law firm who specializes in accelerating healthcare innovation. Nixon Gwilt is a woman owned law firm based in Virgina and it was recommended to SleepSpace by one its investors at Quake Capital. Nixon Gwilt has helped many similar companies successfully create a business model in the healthcare billing ecosystem. In Phase II we will apply what we learned in Phase I to executing on our business model. We will hire Larta Inc to help complete the commercialization aspect of the project. Larta Inc is a SAM-registered and qualified small business entity and a fully owned subsidiary of Larta institute and has been working with SBIR/STTR grantees for the last 15 years. Larta will be responsible for pursuing a different intellectual property strategy, entering the market with our product, and collaborating with commercial partners. Changes in IP strategy may include focusing more or less on our hardware versus software patent portfolio. Based on our findings we may enter the market going through psychologists, pulmonologists, or joint offices. Alternatively, we may focus more on general practitioners and wellness coaches. Ideal corporate partnerships would include fortune 500 companies looking to lower their insurance premiums, insurance providers, hospitals, and living facilities.
期刊论文(20)
专著(0)
科研奖励(0)
会议论文
A non-pharmacological multi-modal therapy to improve sleep and cognition and reduce mild cognitive impairment risk: Design and methodology of a randomized clinical trial.
一种改善睡眠和认知并降低轻度认知障碍风险的非药物多模式疗法:随机临床试验的设计和方法。
DOI: 10.1016/j.cct.2023.107275
发表时间: 2023
期刊: Contemporary clinical trials
影响因子: 2.2
作者: [Emert,SarahE, Taylor,DanielJ, Gartenberg,Daniel, Schade,MargeauxM, Roberts,DanielM, Nagy,SamanthaM, Russell,Michael, Huskey,Alisa, Mueller,Melissa, Gamaldo,Alyssa, Buxton,OrfeuM]
通讯作者: Buxton,OrfeuM
DOI: 10.1186/s12966-023-01509-y
发表时间: 2023-09-12
期刊: INTERNATIONAL JOURNAL OF BEHAVIORAL NUTRITION AND PHYSICAL ACTIVITY
影响因子: 8.7
作者: [Wagner, Julie A., Bermudez-Millan, Angela, Buckley, Thomas E., Buxton, Orfeu M., Feinn, Richard S., Kong, Sengly, Kuoch, Theanvy, Master, Lindsay, Scully, Mary F.]
通讯作者: Scully, Mary F.
DOI: 10.1371/journal.pbio.3001233
发表时间: 2021-06
期刊: PLoS biology
影响因子: 9.8
作者: [Han F, Chen J, Belkin-Rosen A, Gu Y, Luo L, Buxton OM, Liu X, Alzheimer’s Disease Neuroimaging Initiative]
通讯作者: Alzheimer’s Disease Neuroimaging Initiative
DOI: 10.1080/15402002.2021.1902814
发表时间: 2022-03
期刊: Behavioral sleep medicine
影响因子: 3.1
作者: [Ghani SB, Delgadillo ME, Granados K, Okuagu AC, Wills CCA, Alfonso-Miller P, Buxton OM, Patel SR, Ruiz J, Parthasarathy S, Haynes PL, Molina P, Seixas A, Jean-Louis G, Grandner MA]
通讯作者: Grandner MA
共 17 条
    A non-pharmacological multi-modal therapy to improve sleep and cognition and reduce mild cognitive impairment risk
    • 批准号:
      10010093
    • 项目类别:
    • 资助金额:
      $124.35万
    • 财政年份:
      2017
    • 负责人:
      Daniel Gartenberg
    • 依托单位: